Navigation Links
EMEA Validates Cell Therapeutics, Inc.'s (CTI) Expanded Pixantrone Pediatric Investigation Plan (PIP)
Date:8/15/2010

SEATTLE, Aug. 16 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has received notice that the European Medicines Agency ("EMEA") has validated the expanded Pediatric Investigation Plan ("PIP") that CTI filed in July for pixantrone for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL).  Following the validation, the EMEA Pediatric Committee (the "PDCO") will review and comment or approve the content of pediatric plan.  Once the PIP is approved, CTI will submit the Marketing Authorization Application ("MAA") for pixantrone in the E.U. later this year.  The pediatric program will study pixantrone in pediatric patients aged 6 months to 18 years with the goal of determining the comparative safety and effectiveness of pixantrone compared to doxorubicin in pediatric lymphoid cancers.

"We are very pleased that the EMEA has validated the expanded PIP for pixantrone, as there is a real need for a less toxic, more effective anthracycline-like treatment option not only in lymphoma, but also possibly in other tumors," said Jack Singer, Chief Medical Officer of CTI. "We look forward to completing the MAA submission, and continuing to pursue our goal of providing pixantrone as a treatment option to the patients who need it most."

CTI submitted the updated, expanded PIP in July 2010 after the PDCO recommended CTI expand the original PIP of September 2009 to include pixantrone's potential, but unproven, clinical benefit to children in reducing long-term cardiotoxicity associated with current curative therapies. The recommendation from the PDCO came following discussions with CTI about the preclinical and clinical pixantrone data, including PIX301, and the desire to explore the potential benefits pixantrone may offer to children with hematologic cancer.

About PixantronePixantrone is a novel aza-anthracenedione that has distinct structural and physio-che
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Canadas Michael Smith Genome Sciences Center Validates NEBNextâ„¢ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
2. New Funding Validates Importance of Divergence's Work on Nematodes
3. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
4. AMPAC Fine Chemicals Validates Continuous Extraction Process for API Manufacture
5. ActiveCare, Inc. Announces Strategic Relationship With Vista Therapeutics, Inc. in Developing Nano Biosensors for the Elderly
6. Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation
7. Cell Therapeutics, Inc. (CTI) to Present at 21st Annual Piper Jaffray Health Care Conference
8. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
9. Cell Therapeutics, Inc.s (CTI) Presentation at BIO Investor Forum to be Webcast
10. Oxygen Biotherapeutics, Inc. Expands Board of Directors
11. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... W. R. Grace & Co. (NYSE: ... Germany has received good manufacturing practice (GMP) certification ... Pharmaceutical Excipient Council (IPEC) Foundation. , ... FP brand of pharmaceutical grade excipient silica gels ... Bay, Maryland (USA) and Sorocaba, Brazil locations. The ...
(Date:5/21/2015)... 20, 2015 Research and Markets ... the "2015 Global Survey on Flow Cytometry ... The primary goal of this research is ... and reagents. Key information the survey seeks to ... flow cytometers, predominantly used applications for flow cytometers, ...
(Date:5/20/2015)... , May 20, 2015 Veracyte, ... preliminary data demonstrating the ability of the company,s ... (IPF) from other interstitial lung diseases (ILDs) using ... classifier,s potential to help thousands of patients avoid ... in IPF diagnosis – a frequent challenge for ...
(Date:5/20/2015)... May 20, 2015  Select Medical Corporation ("Select") ... Trade Commission granted early termination of the waiting ... of 1976, as amended, applicable to the acquisition ... a joint venture that Select has created with ... As previously announced, MJ Acquisition Corporation has signed ...
Breaking Biology Technology:Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2Global Survey on Flow Cytometry Adoption Trends 2015 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... Fla., June 8 /PRNewswire/ -- Pasteuria Bioscience ... Environmental Protection Agency (EPA) for Pasteuria usgae . ... Pasteuria spp., a natural bacteria prevalent in soil ... for plant-parasitic nematodes. , , "We,re very ...
... a west coast session of NCCN Academy for Excellence ... Business scheduled for July 9 - 10, 2009 in ... give pharmaceutical and biotech professionals the rare opportunity to ... operational issues from the provider and payer perspective. , ...
... Israel, June 8 D-Pharm announced today that its,Investigational New ... DP-b99 in acute ischemic stroke patients has been approved by ... the trial in,the coming months, in over 100 clinical sites ... The forthcoming Phase III trial is a randomized, ...
Cached Biology Technology:Pasteuria Bioscience Receives EPA Registration for Nematode Control 2Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 2Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 3Industry Professionals Get Schooled in Real-World Oncology Issues at NCCN Academy 4D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients 2D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients 3
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)...  higi, a leading cloud-based consumer engagement platform that ... with their communities around health and wellness, announced today ... API.  ... and convenient vehicle to receive validated health information from ... The API will allow higi,s trusted partners, on a ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... of biomedical scientists today is the culture of research ... the lack of "open access" to journal content is ... survey of 883 biomedical scientists ?in Europe and North ... found that aside from lack of resources, a ...
... and vegetables instead of cookies and soda pop. Consider ... applaud a lunchtime workout rather than criticizing the cut ... encourages walking the stairs instead of riding the elevator. ... by Community Health Councils, Inc. (CHC) in Los Angeles ...
... Researchers at New York University have made chemical modifications ... potential to improve magnetic resonance imaging (MRI) techniques. Their ... Letters. , The study was conducted jointly by NYU's ... the NYU School of Medicine. The study is part ...
Cached Biology News:Funding and bureaucracy, not access to journals, are chief obstacles to scientific productivity 2UCLA study of community health project shows how group dynamics affect fitness, eating habits 2UCLA study of community health project shows how group dynamics affect fitness, eating habits 3NYU researchers decorate virus particles, showing potential to enhance MRI capabilities 2
... The reliable and compact GC-8A is Shimadzu's ... Economical and simple to use, the GC-8A ... flow control, on column injection port(s), and ... program models are available. The GC-8A is ...
... The 6820 GC system combines world-class ... Chemical QA/QC software, Agilents world-renowned support and ... consumables and supplies--a combination that lets you ... decisions based on dependable data. The Agilent ...
... Adding an exciting new chapter ... GC leadership, Agilents 7890A GC ... to take your lab to ... and GC/MS performance, including advanced ...
The essence of fluorescence analysis is sensitivity. The high throughput optical system in the RF-5301PC employs a blazed holographic grating, photomultiplier and digital signal processing to provide...
Biology Products: